FDA Collaborating With CDC to Restart Routine On-Site Inspections
The FDA is working with the Centers for Disease Control and Prevention (CDC) to determine how it will restart routine on-site inspections of drug manufacturing facilities, the agency has announced.
FDA Commissioner Stephen Hahn said restarting inspections will be done in phases, backed by scientific data and adhering to the White House’s guidelines for gradually reopening the country.
In March, the agency announced that it would suspend domestic and foreign inspections through April, except for those deemed essential. — James Miessler